Clinical Approach to Upper GI Bleeding
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of upper gastrointestinal bleeding
Upper gastrointestinal bleeding (UGIB) is a common medical emergency, accounting for approximately 300,000 to 350,000 hospital admissions annually in the United States. The incidence ranges from 50 to 150 cases per 100,000 population per year. Despite advances in endoscopic therapy and critical care, mortality remains significant at 2-10% for non-variceal bleeding and 15-20% for variceal bleeding. UGIB is twice as common in men as in women, and incidence increases markedly with age, particularly after 60 years.
Definition
Upper gastrointestinal bleeding refers to hemorrhage originating from a source proximal to the ligament of Treitz (the suspensory ligament of the duodenum at the duodenojejunal junction). This anatomical landmark divides upper from lower gastrointestinal bleeding and encompasses bleeding from the esophagus, stomach, and duodenum.
Classification by Clinical Presentation
| Presentation | Description | Clinical Significance | Typical Source |
|---|---|---|---|
| Hematemesis | Vomiting of fresh red blood or blood clots | Indicates active, often brisk bleeding; source proximal to ligament of Treitz | Esophageal varices, gastric ulcer, Mallory-Weiss tear |
| Coffee-ground emesis | Vomiting of dark, granular material resembling coffee grounds | Blood altered by gastric acid; suggests slower or recently stopped bleeding | Gastric or duodenal ulcer, gastritis |
| Melena | Black, tarry, malodorous stools | Requires approximately 50-100 mL of blood; indicates upper GI source in 90% of cases | Any upper GI source; occasionally proximal colon |
| Hematochezia | Passage of fresh red blood per rectum | Usually lower GI source, but can indicate massive upper GI bleeding with rapid transit | Massive upper GI bleed with blood loss greater than 1000 mL |
| Occult bleeding | Bleeding detected only by fecal occult blood test or iron deficiency anemia | Chronic, low-grade blood loss; requires investigation of entire GI tract | Erosive disease, vascular malformations, malignancy |
Classification by Severity
Massive or Severe Bleeding
Definition: Blood loss causing hemodynamic instability or requiring transfusion of 3 or more units of packed red blood cells within 24 hours.
Clinical features: Hypotension (systolic blood pressure less than 90 mmHg), tachycardia (heart rate greater than 100 beats per minute), altered mental status, oliguria, or syncope.
Mortality: 10-30% depending on etiology and comorbidities.
Non-massive or Minor Bleeding
Definition: Hemodynamically stable bleeding that can often be managed in the outpatient setting or with brief hospitalization.
Clinical features: Normal vital signs, no orthostatic changes, hemoglobin drop of less than 2 g/dL, no ongoing transfusion requirement.
Mortality: Less than 3% in appropriately selected low-risk patients.
Classification by Etiology
| Category | Frequency | Common Causes | Key Distinguishing Features |
|---|---|---|---|
| Non-variceal bleeding | 80-90% | Peptic ulcer disease (35-50%), erosive disease (8-15%), Mallory-Weiss tear (5-15%), malignancy (2-5%), vascular lesions (5%) | Often associated with NSAID or aspirin use, Helicobacter pylori infection; amenable to endoscopic therapy |
| Variceal bleeding | 10-20% | Esophageal varices (most common), gastric varices, portal hypertensive gastropathy | Associated with liver cirrhosis and portal hypertension; higher mortality; requires specific management protocols |
Classification by Timing and Course
| Category | Definition | Clinical Implications |
|---|---|---|
| Acute overt bleeding | Visible bleeding of recent onset (within hours to days) | Requires urgent evaluation and often hospitalization; endoscopy typically within 24 hours |
| Chronic occult bleeding | Slow blood loss over weeks to months, presenting as iron deficiency anemia | Requires complete GI evaluation including upper and lower endoscopy; malignancy must be excluded |
| Recurrent bleeding | Repeat hemorrhage after initial cessation (spontaneous or post-intervention) | Occurs in 10-30% of cases; indicates high-risk lesion or inadequate initial therapy; associated with increased mortality |
Key Concept: The “Big Four” causes of upper gastrointestinal bleeding are peptic ulcer disease (35-50%), erosive esophagitis and gastritis (8-15%), esophageal and gastric varices (10-20%), and Mallory-Weiss tears (5-15%). Together, these account for over 80% of all cases. Recognizing variceal versus non-variceal bleeding early is critical, as management pathways differ significantly.
Major Risk Factors
Non-variceal Bleeding
- Medications: Non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, anticoagulants, antiplatelet agents, corticosteroids
- Infections: Helicobacter pylori infection
- Lifestyle: Alcohol use, smoking
- Comorbidities: Chronic kidney disease, critical illness, mechanical ventilation
- Age: Risk increases substantially after age 60
Variceal Bleeding
- Liver disease: Cirrhosis of any etiology
- Portal hypertension: Hepatic venous pressure gradient greater than 12 mmHg
- Variceal characteristics: Large variceal size, red wale marks, Child-Pugh class C cirrhosis
- Prior bleeding: Previous variceal hemorrhage is the strongest predictor of rebleeding
- Ongoing alcohol use: Continued alcohol consumption in alcoholic liver disease
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of upper gastrointestinal bleeding
Understanding the pathophysiology of upper gastrointestinal bleeding is essential for targeted diagnosis and management. The gastrointestinal mucosa is normally protected by multiple defense mechanisms including the mucus-bicarbonate barrier, mucosal blood flow, epithelial cell turnover, and prostaglandin synthesis. Bleeding occurs when these defenses are overwhelmed or when structural abnormalities develop in the blood vessels supplying the upper gastrointestinal tract.
Normal Mucosal Defense Mechanisms
| Defense Layer | Components | Function | How It Is Compromised |
|---|---|---|---|
| Pre-epithelial | Mucus layer, bicarbonate secretion | Creates pH gradient protecting epithelium from acid; traps bacteria | NSAIDs reduce mucus and bicarbonate; Helicobacter pylori produces urease creating local alkaline environment |
| Epithelial | Tight junctions, rapid cell turnover, surface phospholipids | Physical barrier; damaged cells rapidly replaced (turnover every 3-5 days) | Alcohol disrupts tight junctions; ischemia impairs cell renewal; bile salts damage phospholipid layer |
| Subepithelial | Mucosal blood flow, prostaglandins, growth factors | Delivers oxygen and nutrients; removes acid that penetrates epithelium; prostaglandins stimulate mucus and bicarbonate | NSAIDs inhibit prostaglandin synthesis; shock reduces mucosal perfusion; critical illness causes stress-related mucosal damage |
Pathophysiology by Condition
Peptic Ulcer Disease
The Acid-Mucosal Defense Imbalance
Peptic ulcers develop when aggressive factors (gastric acid, pepsin, Helicobacter pylori, NSAIDs) overwhelm mucosal defenses. Bleeding occurs when ulceration erodes into a blood vessel. The severity depends on the vessel size and location—posterior duodenal ulcers may erode into the gastroduodenal artery, causing massive hemorrhage, while gastric ulcers along the lesser curvature may erode into the left gastric artery.
| Ulcer Location | Vessel at Risk | Bleeding Characteristics | Clinical Implications |
|---|---|---|---|
| Posterior duodenal bulb | Gastroduodenal artery | Often massive, arterial bleeding; high rebleeding rate | May require angiographic embolization or surgery if endoscopic therapy fails |
| Lesser curvature of stomach | Left gastric artery branches | Can be significant; associated with larger ulcers | Higher malignancy risk; biopsy essential |
| Anterior duodenal bulb | Smaller mucosal vessels | Usually self-limited; lower rebleeding rate | More likely to perforate than bleed massively |
| Gastric body and fundus | Short gastric arteries, splenic artery branches | Variable severity | Consider gastric malignancy; multiple biopsies required |
Variceal Bleeding
Portal Hypertension Cascade: Variceal bleeding results from the following sequence:
- Increased portal resistance: Cirrhosis causes architectural distortion and increased intrahepatic resistance
- Splanchnic vasodilation: Nitric oxide and other vasodilators cause mesenteric vasodilation, increasing portal inflow
- Collateral formation: Porto-systemic collaterals develop, including esophageal and gastric varices
- Variceal rupture: Occurs when wall tension exceeds wall strength (LaPlace’s law: wall tension = pressure × radius / wall thickness)
Esophageal Varices
Location: Distal 2-5 cm of esophagus
Mechanism: Collaterals between left gastric vein (portal) and esophageal veins (systemic)
Bleeding threshold: Hepatic venous pressure gradient greater than 12 mmHg
Risk factors for rupture: Large size, red wale marks, high portal pressure, advanced liver disease
Gastric Varices
Location: Gastric fundus and cardia
Mechanism: Collaterals via short gastric and posterior gastric veins
Clinical significance: Less common than esophageal but bleed more severely and are harder to treat endoscopically
Classification: Sarin classification (GOV1, GOV2, IGV1, IGV2) guides management
Portal Hypertensive Gastropathy
Location: Diffuse, primarily gastric body and fundus
Mechanism: Mucosal and submucosal vascular ectasia due to portal hypertension
Bleeding pattern: Usually chronic, occult blood loss causing anemia rather than acute hemorrhage
Appearance: “Snake-skin” or mosaic pattern on endoscopy
Mallory-Weiss Tear
| Aspect | Description |
|---|---|
| Mechanism | Longitudinal mucosal laceration at the gastroesophageal junction caused by sudden increase in intragastric pressure against a closed glottis (forceful vomiting or retching) |
| Location | Gastric side of the gastroesophageal junction (80%); may extend into distal esophagus |
| Predisposing factors | Alcohol use (present in 40-70% of cases), hiatal hernia, severe vomiting from any cause, recent endoscopy |
| Bleeding characteristics | Typically arterial from submucosal arteries; self-limited in 80-90% of cases |
| Natural history | Most heal spontaneously within 48-72 hours without specific therapy |
Erosive Disease
Erosive Esophagitis
- Mechanism: Chronic acid exposure damages esophageal squamous epithelium
- Progression: Inflammation → erosion → ulceration → bleeding
- Bleeding pattern: Usually chronic, occult; occasionally acute if deep ulceration occurs
Erosive Gastritis
- Mechanism: Mucosal injury from NSAIDs, alcohol, stress, or ischemia
- Appearance: Multiple superficial erosions, often in antrum
- Bleeding pattern: Usually minor oozing; rarely causes massive hemorrhage
Summary: How Conditions Cause Upper GI Bleeding
| Condition | Primary Mechanism | Vessel Involved | Treatment Implication |
|---|---|---|---|
| Peptic ulcer disease | Acid-pepsin injury eroding through mucosa to vessels; Helicobacter pylori and NSAID-induced mucosal damage | Submucosal or deeper arteries (gastroduodenal, left gastric) | Acid suppression heals ulcer; endoscopic therapy stops active bleeding; Helicobacter pylori eradication prevents recurrence |
| Esophageal varices | Portal hypertension causes collateral formation; elevated wall tension leads to rupture | Porto-systemic venous collaterals | Reduce portal pressure (vasoactive drugs, TIPS); endoscopic band ligation; antibiotic prophylaxis for infection |
| Gastric varices | Similar to esophageal varices but via different collateral pathways | Short gastric and posterior gastric veins | Cyanoacrylate injection or TIPS; band ligation less effective |
| Mallory-Weiss tear | Rapid intragastric pressure rise causes mucosal laceration | Submucosal arteries at gastroesophageal junction | Usually self-limited; endoscopic therapy if active bleeding; control vomiting |
| Dieulafoy lesion | Aberrant submucosal artery fails to taper normally, erodes through mucosa | Abnormally large submucosal artery (1-3 mm diameter) | Endoscopic therapy highly effective; lesion can be subtle and easily missed |
| Gastric antral vascular ectasia (watermelon stomach) | Dilated mucosal capillaries with fibromuscular hyperplasia | Mucosal capillary ectasias | Argon plasma coagulation; may require multiple sessions; iron supplementation for chronic blood loss |
| Upper GI malignancy | Tumor neovascularization and invasion into vessels; tumor necrosis | Variable—tumor vessels or invaded adjacent arteries | Endoscopic therapy often temporizing; definitive treatment requires addressing underlying malignancy |
Often Overlooked: The Dieulafoy Lesion
A Dieulafoy lesion is an abnormally large submucosal artery (1-3 mm diameter compared to normal 0.1-0.2 mm) that erodes through the mucosa without an associated ulcer. It typically presents with massive, intermittent bleeding and can be easily missed on endoscopy if not actively bleeding, as the overlying mucosa appears normal. The most common location is the proximal stomach along the lesser curvature within 6 cm of the gastroesophageal junction. A high index of suspicion and careful examination are essential—repeat endoscopy may be required to identify the lesion.
Natural Hemostasis and Factors Affecting Rebleeding
| Factor | Effect on Hemostasis | Clinical Relevance |
|---|---|---|
| Gastric pH | Clot stability requires pH greater than 6; acid environment impairs platelet aggregation and accelerates clot lysis | High-dose proton pump inhibitor therapy maintains gastric pH above 6 to promote hemostasis |
| Vessel size | Larger vessels (greater than 2 mm) have higher failure rates with endoscopic therapy | Visible vessel on endoscopy predicts rebleeding; dual endoscopic therapy recommended |
| Ulcer location | Posterior duodenal bulb and lesser curvature ulcers near major arteries carry higher rebleeding risk | Consider early surgical or interventional radiology consultation for high-risk locations |
| Coagulopathy | Impaired clot formation prolongs bleeding and increases rebleeding risk | Correct coagulopathy; reverse anticoagulation when appropriate (balancing thrombotic risk) |
| Hemodynamic status | Hypotension reduces tissue perfusion; resuscitation improves mucosal healing | Adequate resuscitation before endoscopy improves outcomes |
3. History Taking
A comprehensive approach to eliciting the upper gastrointestinal bleeding history
Red Flags — Require Urgent Evaluation
- Hemodynamic instability — Syncope, presyncope, altered mental status suggest massive blood loss
- Large volume hematemesis — Fresh red blood or large clots indicate active, brisk bleeding
- Hematochezia with upper GI symptoms — Suggests massive upper GI hemorrhage with rapid transit
- Known or suspected liver disease — Variceal bleeding carries 15-20% mortality
- Ongoing anticoagulation — May have uncontrolled bleeding; reversal decisions needed
- Chest pain or dyspnea — Consider myocardial ischemia from anemia, aspiration, or aortoenteric fistula
- Recent aortic surgery or known aortic aneurysm — Aortoenteric fistula is life-threatening
- Severe abdominal pain — May indicate perforation accompanying the bleeding ulcer
Systematic History: The “BLEEDING” Approach
Use the mnemonic “BLEEDING” to ensure comprehensive history taking for upper gastrointestinal hemorrhage:
- B — Blood appearance: What does the blood look like? Bright red hematemesis, coffee-ground emesis, melena, or hematochezia? Volume estimate?
- L — Liver disease history: Any known cirrhosis, hepatitis, alcohol use disorder, or signs of chronic liver disease?
- E — Episodes and timing: When did bleeding start? How many episodes? Is it ongoing or has it stopped?
- E — Exacerbating factors: Recent vomiting or retching before hematemesis (Mallory-Weiss)? Recent heavy alcohol use?
- D — Drugs and medications: NSAIDs, aspirin, anticoagulants, antiplatelet agents, corticosteroids, SSRIs?
- I — Indigestion and ulcer symptoms: Epigastric pain, dyspepsia, heartburn, prior peptic ulcer disease, Helicobacter pylori status?
- N — Nutrition and weight: Unintentional weight loss, dysphagia, early satiety suggesting malignancy?
- G — General symptoms: Fatigue, weakness, lightheadedness, chest pain, dyspnea suggesting significant anemia?
Characterizing the Bleeding Episode
| Question | Why It Matters | Clinical Interpretation |
|---|---|---|
| “What color was the blood you vomited?” | Distinguishes active from recent bleeding | Bright red = active bleeding; Coffee-ground = blood exposed to gastric acid (slower or stopped bleeding) |
| “How much blood have you lost?” | Helps estimate severity (though patients often over- or underestimate) | Tablespoon versus cupful versus bowl; number of episodes; soaked clothing or bedding |
| “What color are your stools?” | Melena confirms upper GI source in most cases | Black and tarry = melena (upper GI); Maroon or bright red with hematemesis = massive upper GI bleed |
| “Did you vomit before the blood appeared?” | Forceful vomiting preceding hematemesis suggests Mallory-Weiss tear | Classic history: non-bloody vomiting followed by hematemesis |
| “Have you felt dizzy, lightheaded, or fainted?” | Symptoms of hypovolemia indicate significant blood loss | Syncope suggests loss of greater than 20% blood volume; requires urgent resuscitation |
| “When did you last pass urine, and how much?” | Oliguria is a sign of significant hypovolemia | Decreased urine output suggests inadequate end-organ perfusion |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Peptic ulcer disease | Epigastric pain, relation to meals, history of Helicobacter pylori or NSAID use | “Do you have burning pain in your upper abdomen? Does eating make it better or worse?” |
| Esophageal varices | Known liver disease, alcohol use, prior variceal bleeding | “Have you ever been told you have liver problems, cirrhosis, or hepatitis? How much alcohol do you drink?” |
| Mallory-Weiss tear | Forceful vomiting or retching before hematemesis, alcohol binge | “Were you vomiting or retching before you saw blood? Had you been drinking alcohol heavily?” |
| Erosive esophagitis | Chronic heartburn, regurgitation, dysphagia | “Do you have frequent heartburn or acid reflux? Do you take any medications for this?” |
| Gastric malignancy | Weight loss, early satiety, dysphagia, family history | “Have you lost weight without trying? Do you feel full quickly after eating? Any difficulty swallowing?” |
| Aortoenteric fistula | History of aortic aneurysm repair, “herald bleed” followed by massive hemorrhage | “Have you ever had surgery on your aorta or a stent placed in your abdomen?” |
| NSAID-induced gastropathy | Chronic NSAID use, often asymptomatic until bleeding | “Do you take ibuprofen, naproxen, or any other pain medications regularly? Including over-the-counter?” |
| Dieulafoy lesion | Recurrent, massive, intermittent bleeding without preceding symptoms | “Have you had episodes of sudden, severe bleeding that then stopped on its own?” |
Medication and Substance History
Medications That Cause or Exacerbate Upper GI Bleeding
- NSAIDs (including aspirin) — Inhibit prostaglandin synthesis, impair mucosal defense; even low-dose aspirin increases risk 2-4 fold
- Anticoagulants — Warfarin, direct oral anticoagulants (rivaroxaban, apixaban, dabigatran, edoxaban), heparin; prolong bleeding once it starts
- Antiplatelet agents — Clopidogrel, prasugrel, ticagrelor; especially high risk when combined with aspirin
- Corticosteroids — Increase risk when combined with NSAIDs; impair wound healing
- SSRIs — Selective serotonin reuptake inhibitors impair platelet function; increase risk 1.5-2 fold, especially with NSAIDs
- Bisphosphonates — Can cause esophageal erosions and ulceration, especially if taken incorrectly
- Potassium chloride — Can cause localized mucosal injury
Substance and Social History
- Alcohol: Quantify intake (drinks per day/week); alcohol causes gastritis, Mallory-Weiss tears, and is the leading cause of cirrhosis and varices
- Tobacco: Impairs ulcer healing, increases risk of peptic ulcer disease and malignancy
- Illicit drugs: Cocaine causes vasoconstriction and mucosal ischemia
- Recent binge drinking: Associated with acute gastritis and Mallory-Weiss tears
Prior GI History
- Previous upper GI bleeding: Strongest predictor of recurrence
- Known peptic ulcer disease: Recurrence rate without Helicobacter pylori treatment is 60-80%
- Prior endoscopy findings: Previous varices, ulcers, or vascular lesions
- Helicobacter pylori status: Previous testing and treatment
Relevant Comorbidities to Assess
| Comorbidity | Why It Matters | Key Questions |
|---|---|---|
| Chronic liver disease | Portal hypertension causes varices; coagulopathy worsens bleeding; higher mortality | Known cirrhosis? Hepatitis B or C? Alcohol use? Previous ascites or encephalopathy? |
| Cardiovascular disease | Anemia may precipitate ischemia; antiplatelet agents cannot be easily stopped | Coronary artery disease? Recent stent? Atrial fibrillation? Heart failure? |
| Chronic kidney disease | Uremic platelet dysfunction; altered drug metabolism; higher bleeding risk | Known kidney disease? On dialysis? |
| Coagulation disorders | Underlying bleeding diathesis may contribute; affects management | History of easy bruising or prolonged bleeding? Known clotting disorder? |
| Malignancy | GI malignancy may be source; other malignancies may cause coagulopathy | Any history of cancer? Unexplained weight loss? Previous chemotherapy? |
The “Herald Bleed” of Aortoenteric Fistula
In any patient with a history of aortic aneurysm repair (open or endovascular) presenting with gastrointestinal bleeding, consider aortoenteric fistula until proven otherwise. The classic presentation is a self-limited “herald bleed” (often appearing minor) followed hours to weeks later by catastrophic, exsanguinating hemorrhage. The fistula typically occurs between the aortic graft and the third or fourth portion of the duodenum. CT angiography is the diagnostic test of choice, though endoscopy may show the fistula or erosion. This diagnosis is a surgical emergency with mortality exceeding 50% even with treatment.
4. Physical Examination
A systematic approach for patients presenting with upper gastrointestinal bleeding
Systematic Framework: The examination of a patient with upper gastrointestinal bleeding has two primary goals: (1) assess hemodynamic status and severity of blood loss, and (2) identify clues to the underlying etiology. Use the “Hemodynamics First, Then Head-to-Toe” approach.
Vital Signs — The Critical First Step
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Heart Rate | Tachycardia (greater than 100 beats per minute) | Early sign of hypovolemia; may be blunted by beta-blockers (common in cirrhotic patients on non-selective beta-blockers) |
| Blood Pressure | Hypotension (systolic less than 90 mmHg) or relative hypotension | Indicates significant blood loss (typically greater than 30% blood volume); may be late finding in young patients |
| Orthostatic Vital Signs | Increase in heart rate greater than 20 bpm or decrease in systolic BP greater than 20 mmHg upon standing | Suggests 15-20% blood volume loss; useful in patients who appear hemodynamically stable supine |
| Respiratory Rate | Tachypnea (greater than 20 breaths per minute) | Compensatory response to anemia (increased oxygen delivery); also consider aspiration if coughing |
| Oxygen Saturation | May be preserved until severe anemia | Saturation measures percentage of hemoglobin saturated, not oxygen-carrying capacity; can be falsely reassuring |
| Temperature | Fever | May indicate infection (spontaneous bacterial peritonitis in cirrhosis, infected necrotic tumor, or aspiration pneumonia) |
Shock Index: A Useful Bedside Tool
Shock Index = Heart Rate ÷ Systolic Blood Pressure
Normal value is 0.5 to 0.7. A shock index greater than 1.0 indicates significant hypovolemia and predicts need for transfusion, intensive care, and higher mortality. It is more sensitive than either heart rate or blood pressure alone for detecting early shock.
Example: Heart rate 110, systolic BP 95 → Shock index = 1.16 → High risk
General Inspection
- Level of consciousness: Altered mental status suggests severe hypovolemia with cerebral hypoperfusion, hepatic encephalopathy in cirrhosis, or both
- Distress level: Patient actively vomiting blood versus comfortable suggests ongoing versus stopped bleeding
- Skin color: Pallor of conjunctivae, palms, and nail beds indicates anemia; jaundice suggests liver disease
- Diaphoresis: Cool, clammy skin is a sign of shock and sympathetic activation
- Respiratory effort: Labored breathing may indicate aspiration or severe anemia
- Evidence of active bleeding: Blood on clothing, bedding, or emesis basin; check the emesis and stool directly
Signs of Chronic Liver Disease
Identifying stigmata of chronic liver disease is critical as it suggests variceal bleeding and significantly impacts management.
Skin Findings
- Jaundice (scleral icterus)
- Spider angiomata (telangiectasias)
- Palmar erythema
- Caput medusae (periumbilical varices)
- Terry’s nails (white nail beds)
- Bruising (coagulopathy)
Abdominal Findings
- Ascites (shifting dullness, fluid wave)
- Hepatomegaly or small, shrunken liver
- Splenomegaly (portal hypertension)
- Dilated abdominal wall veins
Other Findings
- Asterixis (hepatic encephalopathy)
- Fetor hepaticus (sweet, musty breath)
- Gynecomastia
- Testicular atrophy
- Muscle wasting
- Dupuytren contractures
Head and Neck Examination
| Area | What to Examine | Findings and Significance |
|---|---|---|
| Eyes | Conjunctivae, sclera | Conjunctival pallor indicates anemia (hemoglobin less than 9-10 g/dL); scleral icterus indicates hyperbilirubinemia (liver disease) |
| Oral cavity | Mucous membranes, blood in mouth | Pale mucosa suggests anemia; dried blood or fresh blood in oropharynx confirms recent hematemesis; telangiectasias suggest hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) |
| Neck | Jugular venous pressure, lymphadenopathy | Flat neck veins suggest hypovolemia; elevated JVP with bleeding is concerning for cardiac disease; left supraclavicular node (Virchow node) suggests gastric malignancy |
| Parotid glands | Bilateral enlargement | Parotid hypertrophy suggests chronic alcohol use |
Cardiovascular Examination
- Peripheral perfusion: Cool extremities, delayed capillary refill (greater than 3 seconds), and mottled skin suggest poor peripheral perfusion due to hypovolemia
- Heart sounds: Hyperdynamic circulation with flow murmur may be present in significant anemia; gallop rhythm suggests cardiac decompensation
- Peripheral pulses: Weak, thready pulses indicate hypovolemia; assess for pulse deficit in atrial fibrillation (relevant for anticoagulation status)
- Peripheral edema: May indicate heart failure, liver disease with hypoalbuminemia, or nephrotic syndrome
Abdominal Examination
Inspection
- Abdominal distension (ascites, bowel obstruction)
- Visible veins (caput medusae in portal hypertension)
- Surgical scars (previous surgery, aortic repair suggesting aortoenteric fistula risk)
- Visible pulsatile mass (abdominal aortic aneurysm)
Palpation
- Tenderness: Epigastric tenderness suggests peptic ulcer disease or gastritis; diffuse tenderness with guarding suggests perforation
- Hepatomegaly: May indicate liver disease, congestion, or malignancy; note texture (firm, nodular in cirrhosis)
- Splenomegaly: Suggests portal hypertension
- Masses: Palpable abdominal mass may indicate malignancy or aortic aneurysm
- Ascites: Check for shifting dullness and fluid wave; tense ascites increases variceal pressure
Auscultation
- Bowel sounds: Hyperactive bowel sounds are common with upper GI bleeding due to the cathartic effect of blood in the intestines
- Bruits: Abdominal bruit may indicate vascular abnormality
Rectal Examination
Essential in All Patients with GI Bleeding
The rectal examination provides critical diagnostic information and should not be omitted.
- Stool color: Melena (black, tarry, sticky, malodorous) indicates upper GI source; bright red blood or maroon stool with upper GI symptoms suggests massive upper GI bleeding
- Stool consistency: Liquid melena suggests more recent or active bleeding than formed melenic stool
- Hemorrhoids: External hemorrhoids are visible; internal hemorrhoids may cause bright red rectal bleeding but do not cause melena
- Masses: Rectal mass requires further investigation
- Prostate (in males): Enlarged prostate may complicate urinary catheterization if needed
Extremities Examination
- Peripheral perfusion: Cool, pale, or mottled extremities indicate shock
- Edema: Bilateral lower extremity edema suggests hypoalbuminemia (liver disease), heart failure, or nephrotic syndrome
- Clubbing: May indicate chronic liver disease, inflammatory bowel disease, or malignancy
- Palmar erythema: Suggests chronic liver disease
- Dupuytren contracture: Associated with chronic alcohol use and liver disease
- Bruising: Excessive bruising suggests coagulopathy
Expected Physical Examination Findings by Etiology
| Condition | Vital Signs | Key Examination Findings | Often Absent Findings |
|---|---|---|---|
| Peptic ulcer disease | Variable; may be stable or shocked depending on severity | Epigastric tenderness; otherwise often normal | Signs of liver disease |
| Variceal bleeding | Often hemodynamically unstable; may have hypotension despite ongoing resuscitation | Stigmata of chronic liver disease (jaundice, spider angiomata, ascites, splenomegaly, encephalopathy) | May lack obvious stigmata in early or compensated cirrhosis |
| Mallory-Weiss tear | Often hemodynamically stable unless severe | May show signs of recent alcohol intoxication; otherwise often normal | Typically no abdominal findings; liver stigmata uncommon unless concurrent cirrhosis |
| Erosive esophagitis or gastritis | Usually stable | Often entirely normal examination | May have no tenderness despite active bleeding |
| Gastric malignancy | Variable | Cachexia, palpable mass, Virchow node (left supraclavicular), Sister Mary Joseph nodule (periumbilical), hepatomegaly if metastatic | May be normal in early disease |
| Aortoenteric fistula | Initially stable with herald bleed; rapidly deteriorates with massive hemorrhage | Previous midline abdominal surgical scar; pulsatile abdominal mass | May appear deceptively well during herald bleed phase |
Important Teaching Point
The physical examination can be entirely normal in many causes of upper GI bleeding. Peptic ulcer disease, Mallory-Weiss tears, erosive gastritis, Dieulafoy lesions, and even early gastric cancer may present with completely normal physical examination findings aside from evidence of blood loss (pallor, tachycardia). A normal abdominal examination does not exclude significant or even life-threatening pathology. The history and clinical presentation, not the physical examination, guide the urgency of investigation and management.
Rapid Bedside Assessment Checklist
Within the first 5 minutes, assess:
- Airway: Is the airway protected? Risk of aspiration from ongoing hematemesis?
- Hemodynamic status: Heart rate, blood pressure, shock index, mental status
- Estimate blood loss: Inspect emesis and stool; check for orthostatic changes
- Signs of liver disease: Quick scan for jaundice, ascites, spider angiomata (suggests variceal source)
- IV access status: Large-bore IV access needed; assess if additional access required
- Active bleeding: Is there ongoing hematemesis or fresh melena indicating active bleeding?
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
The differential diagnosis of upper gastrointestinal bleeding is broad, but a probability-based approach focusing on the most common causes while remaining vigilant for serious conditions ensures efficient and safe clinical reasoning. The first critical distinction is between variceal and non-variceal bleeding, as management pathways differ significantly.
Non-Variceal Upper GI Bleeding (80-90% of cases)
| Probability | Condition | Frequency | Key Features | Red Flags |
|---|---|---|---|---|
| COMMON | Peptic ulcer disease (gastric and duodenal ulcers) | 35-50% | Epigastric pain, NSAID or aspirin use, Helicobacter pylori infection, prior ulcer history | Posterior duodenal ulcer (gastroduodenal artery erosion), refractory to therapy |
| COMMON | Erosive esophagitis | 5-15% | Chronic heartburn, regurgitation, dysphagia, obesity | Severe esophagitis (Los Angeles grade C or D), Barrett esophagus |
| COMMON | Erosive gastritis and duodenitis | 5-10% | NSAID use, alcohol, critical illness, recent stress | Multiple erosions, ongoing NSAID requirement |
| COMMON | Mallory-Weiss tear | 5-15% | Forceful vomiting or retching preceding hematemesis, alcohol use | Deep laceration, arterial bleeding, coagulopathy |
| LESS COMMON | Gastric malignancy (adenocarcinoma) | 2-5% | Weight loss, early satiety, dysphagia, anemia, age greater than 55 years | Any gastric ulcer requires biopsy to exclude malignancy |
| LESS COMMON | Esophageal malignancy | 1-3% | Progressive dysphagia, weight loss, smoking, alcohol history | Obstruction, fistula formation |
| LESS COMMON | Angiodysplasia (arteriovenous malformations) | 2-5% | Elderly patients, chronic kidney disease, aortic stenosis (Heyde syndrome) | Recurrent bleeding, difficult to treat definitively |
| LESS COMMON | Dieulafoy lesion | 1-2% | Massive intermittent bleeding, no preceding symptoms, proximal stomach | Easily missed on endoscopy if not actively bleeding |
| UNCOMMON BUT SERIOUS | Aortoenteric fistula | Less than 1% | Prior aortic surgery or aneurysm, herald bleed followed by massive hemorrhage | Mortality exceeds 50%; surgical emergency |
| UNCOMMON BUT SERIOUS | Hemobilia | Less than 1% | Recent hepatobiliary procedure, trauma, hepatic artery aneurysm; Quincke triad (biliary colic, jaundice, GI bleeding) | May require angiographic embolization |
| UNCOMMON BUT SERIOUS | Hemosuccus pancreaticus | Very rare | Bleeding from pancreatic duct; chronic pancreatitis, pseudoaneurysm | Intermittent bleeding, difficult diagnosis |
Variceal Upper GI Bleeding (10-20% of cases)
Key Point: Variceal bleeding occurs in the setting of portal hypertension, most commonly due to cirrhosis. It carries significantly higher mortality (15-20%) than non-variceal bleeding and requires specific management including vasoactive drugs, antibiotics, and often endoscopic band ligation or sclerotherapy.
| Condition | Frequency in Variceal Bleeding | Key Distinguishing Features | Management Considerations |
|---|---|---|---|
| Esophageal varices | 70-80% of variceal bleeding | Known cirrhosis, stigmata of chronic liver disease, massive hematemesis | Band ligation is treatment of choice; vasoactive drugs (octreotide, terlipressin) |
| Gastric varices | 20-30% of variceal bleeding | More severe bleeding, harder to control endoscopically; classified by Sarin system (GOV1, GOV2, IGV1, IGV2) | Cyanoacrylate injection or TIPS for fundal varices; band ligation for GOV1 |
| Portal hypertensive gastropathy | 5-10% of portal hypertensive bleeding | Usually chronic occult blood loss rather than acute hemorrhage; “snake-skin” or mosaic pattern | Non-selective beta-blockers; iron supplementation; TIPS if refractory |
| Gastric antral vascular ectasia (GAVE) | Variable; often associated with cirrhosis | “Watermelon stomach” appearance; chronic blood loss and iron deficiency anemia | Argon plasma coagulation; multiple sessions often needed |
| Ectopic varices | Rare (less than 5%) | Varices in duodenum, jejunum, or at stomal sites; previous abdominal surgery | May require interventional radiology or surgery |
Anatomical Approach to Differential Diagnosis
Esophagus
Esophageal varices
Erosive esophagitis
Esophageal ulcer
Esophageal malignancy
Mallory-Weiss tear (GE junction)
Infectious esophagitis (Candida, CMV, HSV)
Pill esophagitis
Boerhaave syndrome (rare)
Stomach
Gastric ulcer
Erosive gastritis
Gastric varices
Gastric malignancy
Dieulafoy lesion
Gastric antral vascular ectasia
Portal hypertensive gastropathy
Gastric polyps
Gastrointestinal stromal tumor (GIST)
Duodenum
Duodenal ulcer
Erosive duodenitis
Duodenal varices
Aortoenteric fistula
Duodenal malignancy (rare)
Ampullary tumors
Hemobilia (via ampulla)
Hemosuccus pancreaticus (via ampulla)
Other Sources (Mimics)
Nasopharyngeal bleeding (swallowed blood)
Hemoptysis (swallowed blood)
Oropharyngeal lesions
Brisk lower GI bleeding with oral transit
Munchausen syndrome (factitious)
Drug-Induced Upper GI Bleeding
| Drug or Drug Class | Mechanism | Characteristics | Management Considerations |
|---|---|---|---|
| Non-steroidal anti-inflammatory drugs (NSAIDs) | Inhibit cyclooxygenase, reducing prostaglandin-mediated mucosal protection; direct topical injury | Gastric ulcers more common than duodenal; may be asymptomatic until bleeding; risk increases with dose and duration | Discontinue if possible; add proton pump inhibitor; consider COX-2 selective inhibitor if NSAID essential |
| Aspirin (including low-dose) | Irreversible COX-1 inhibition; impairs platelet function | Even 81 mg daily increases GI bleeding risk 2-4 fold; both ulcerogenic and antiplatelet effects | Balance cardiovascular benefit versus GI risk; proton pump inhibitor co-therapy in high-risk patients |
| Anticoagulants (warfarin, direct oral anticoagulants) | Impair clotting cascade; do not cause ulcers but promote bleeding from existing lesions | Prolonged or severe bleeding; may unmask occult lesions | Reversal agents available (vitamin K, idarucizumab, andexanet alfa, prothrombin complex concentrate); balance thrombotic risk |
| Antiplatelet agents (clopidogrel, prasugrel, ticagrelor) | Inhibit platelet aggregation | Increased bleeding risk especially when combined with aspirin (dual antiplatelet therapy) | Platelet transfusion if severe bleeding; cardiology consultation before stopping post-stent |
| Corticosteroids | Impair mucosal healing; increase risk synergistically with NSAIDs | Rarely cause bleeding alone; significant risk when combined with NSAIDs | Proton pump inhibitor prophylaxis when used with NSAIDs |
| Selective serotonin reuptake inhibitors (SSRIs) | Deplete platelet serotonin stores, impairing platelet aggregation | Increase GI bleeding risk 1.5-2 fold, especially with NSAIDs | Consider proton pump inhibitor in high-risk patients on SSRIs |
| Bisphosphonates (alendronate, risedronate) | Direct mucosal irritation in esophagus | Esophageal erosions and ulcers; improper administration increases risk | Ensure proper administration (upright position, full glass of water); switch to IV if esophageal injury |
| Potassium chloride supplements | Direct mucosal toxicity, especially slow-release formulations | Localized ulceration, typically small bowel but can affect any level | Use liquid formulation; avoid in GI dysmotility |
Step-by-Step Diagnostic Approach
Systematic Approach to Upper GI Bleeding Differential:
- Step 1: Variceal or Non-variceal? — Look for signs of chronic liver disease; if present, assume variceal until proven otherwise and initiate variceal bleeding protocol
- Step 2: Assess severity — Hemodynamic status determines urgency; massive bleeding requires immediate resuscitation and urgent endoscopy
- Step 3: Review medications — NSAID, aspirin, anticoagulant, and antiplatelet use points toward peptic disease and informs management
- Step 4: Consider clinical context — Forceful vomiting suggests Mallory-Weiss; weight loss suggests malignancy; prior aortic surgery mandates exclusion of aortoenteric fistula
- Step 5: Endoscopy is diagnostic — Upper endoscopy identifies the source in greater than 90% of cases and should be performed within 24 hours (or urgently if hemodynamically unstable)
Quick Reference: “If You See This, Think This First”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Jaundice, ascites, spider angiomata | Variceal bleeding from portal hypertension | Start vasoactive drug and antibiotics; urgent endoscopy for band ligation |
| NSAID or aspirin use with epigastric pain | Peptic ulcer disease | Stop NSAID; proton pump inhibitor; endoscopy within 24 hours |
| Vomiting before hematemesis | Mallory-Weiss tear | Usually self-limited; endoscopy confirms diagnosis; antiemetics |
| Weight loss, dysphagia, age greater than 55 | Upper GI malignancy | Urgent endoscopy with biopsy; staging if confirmed |
| Prior aortic surgery or known aneurysm | Aortoenteric fistula | CT angiography; vascular surgery consultation; do not delay for endoscopy if high suspicion |
| Chronic kidney disease, aortic stenosis, elderly | Angiodysplasia (Heyde syndrome if with aortic stenosis) | Endoscopy; consider capsule endoscopy if upper and lower endoscopy negative |
| Massive intermittent bleeding, normal-appearing mucosa | Dieulafoy lesion | Careful endoscopic examination; may require repeat endoscopy during active bleeding |
| Recent hepatobiliary procedure, right upper quadrant pain, jaundice | Hemobilia | CT angiography; angiographic embolization often required |
| Iron deficiency anemia in cirrhotic patient, “watermelon” pattern | Gastric antral vascular ectasia (GAVE) | Argon plasma coagulation; multiple sessions; iron replacement |
| On anticoagulation with minor bleeding | Underlying lesion unmasked by anticoagulation | Endoscopy to identify source; balance bleeding versus thrombotic risk for reversal decision |
Never Forget: Aortoenteric Fistula
In any patient with a history of abdominal aortic aneurysm repair (open or endovascular, even decades prior), GI bleeding MUST raise suspicion for aortoenteric fistula. The classic presentation is a self-limited “herald bleed” followed by catastrophic hemorrhage. CT angiography is the diagnostic test of choice. A negative endoscopy does NOT exclude this diagnosis—the fistula may not be visible, or active bleeding may not be present at the time of endoscopy. Maintain a high index of suspicion and involve vascular surgery early.
6. Diagnostic Investigations
A stepwise, evidence-based approach guided by clinical suspicion
The investigation of upper gastrointestinal bleeding is driven by two goals: (1) assess the severity of blood loss and physiological impact, and (2) identify the source and etiology to guide definitive management. Endoscopy is the cornerstone of diagnosis and is often therapeutic.
Baseline Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete blood count (CBC) | Assess hemoglobin level and platelet count | Hemoglobin level (may be falsely normal in acute bleeding before hemodilution); thrombocytopenia (cirrhosis, DIC) | Hemoglobin may take 24-72 hours to equilibrate; do not rely on initial hemoglobin to assess severity in acute bleeding |
| Blood type and crossmatch | Prepare for potential transfusion | Blood type; antibody screen | Type and screen for stable patients; type and crossmatch 2-6 units for significant bleeding |
| Coagulation studies (PT/INR, aPTT) | Assess coagulation status; identify anticoagulation effect | Elevated INR (warfarin, liver disease); prolonged aPTT (heparin, liver disease, factor deficiency) | Guides reversal decisions; INR greater than 2.5 associated with increased rebleeding risk |
| Basic metabolic panel (electrolytes, creatinine, BUN) | Assess renal function; detect metabolic derangements | Elevated BUN:creatinine ratio (greater than 30:1 suggests upper GI bleeding—blood digestion increases BUN); acute kidney injury from hypovolemia | BUN:creatinine ratio helps distinguish upper from lower GI source; guide fluid resuscitation |
| Liver function tests (ALT, AST, bilirubin, albumin) | Identify liver disease suggesting variceal source | Elevated bilirubin, low albumin, elevated transaminases suggest cirrhosis | Helps calculate Child-Pugh and MELD scores for prognosis in cirrhosis |
| Lactate | Assess tissue perfusion | Elevated lactate (greater than 2 mmol/L) indicates hypoperfusion or shock | Serial lactate clearance guides adequacy of resuscitation |
| Electrocardiogram (ECG) | Detect myocardial ischemia from anemia | ST changes, arrhythmias | Perform in patients with cardiac history, elderly, or significant anemia |
Risk Stratification Scores
Glasgow-Blatchford Score (GBS)
Purpose: Pre-endoscopy risk stratification; identifies low-risk patients who may not require admission
Components: BUN, hemoglobin, systolic blood pressure, heart rate, melena, syncope, hepatic disease, heart failure
Interpretation:
- GBS = 0: Very low risk; may be suitable for outpatient management
- GBS 1-11: Intermediate risk; typically requires admission
- GBS ≥12: High risk; likely to need intervention
Rockall Score
Purpose: Post-endoscopy risk stratification; predicts rebleeding and mortality
Components: Age, shock, comorbidities, endoscopic diagnosis, stigmata of recent hemorrhage
Interpretation:
- Score 0-2: Low risk (rebleeding less than 5%, mortality less than 1%)
- Score 3-5: Intermediate risk
- Score ≥6: High risk (rebleeding greater than 25%, mortality greater than 15%)
Upper Endoscopy (Esophagogastroduodenoscopy)
The Cornerstone of Diagnosis and Treatment
Upper endoscopy is both diagnostic and therapeutic in upper GI bleeding. It identifies the bleeding source in greater than 90% of cases and allows for immediate hemostatic intervention when indicated.
| Aspect | Recommendation | Rationale |
|---|---|---|
| Timing | Within 24 hours for most patients; within 12 hours for high-risk features; emergent (less than 6 hours) if hemodynamically unstable despite resuscitation | Early endoscopy improves outcomes by enabling diagnosis and hemostasis; very early endoscopy (less than 6 hours) may not improve mortality but does decrease length of stay |
| Pre-endoscopy resuscitation | Stabilize hemodynamics, correct severe coagulopathy (INR less than 2.5 ideal), consider airway protection | Adequate resuscitation improves visualization and reduces complications; intubation may be needed for massive hematemesis or encephalopathy |
| Prokinetic agents | Erythromycin 250 mg IV or metoclopramide 10 mg IV 30-90 minutes before endoscopy | Improves gastric visualization by promoting emptying of blood and clots; reduces need for repeat endoscopy |
| Forrest classification (for ulcers) | Document endoscopic findings using standardized classification | Predicts rebleeding risk: Ia (spurting) 90%, Ib (oozing) 30%, IIa (visible vessel) 50%, IIb (adherent clot) 30%, IIc (flat spot) 10%, III (clean base) 5% |
| Therapeutic intervention | Combination therapy (injection plus thermal or mechanical) for high-risk lesions | Dual therapy superior to monotherapy for reducing rebleeding; clips or thermal coagulation after epinephrine injection |
Targeted Investigations by Suspected Etiology
If Suspecting Peptic Ulcer Disease
First-Line Tests
- Esophagogastroduodenoscopy: Identifies and treats ulcer; documents Forrest classification
- Helicobacter pylori testing: Rapid urease test (CLO test) on biopsy; histology; consider stool antigen or urea breath test if biopsy negative (false negatives in acute bleeding)
- Biopsy of gastric ulcers: Multiple biopsies (at least 6-8) from ulcer margins to exclude malignancy
Follow-up Testing
- Repeat endoscopy (6-8 weeks): Document healing; repeat biopsy of gastric ulcers to confirm benign nature
- Confirm Helicobacter pylori eradication: Urea breath test or stool antigen at least 4 weeks after completing treatment (and off proton pump inhibitors for 2 weeks)
- Fasting gastrin level: If recurrent or refractory ulcers, consider Zollinger-Ellison syndrome
If Suspecting Variceal Bleeding
First-Line Tests
- Esophagogastroduodenoscopy: Confirms varices; allows band ligation or sclerotherapy
- Liver function tests and coagulation: Assess severity of liver disease
- Complete blood count: Thrombocytopenia common in portal hypertension
- Paracentesis (if ascites): Rule out spontaneous bacterial peritonitis
Assessment of Liver Disease
- Child-Pugh score: Guides prognosis and management (Class A, B, or C)
- MELD score: Predicts 90-day mortality; guides transplant listing
- Abdominal ultrasound with Doppler: Assess liver architecture, portal vein patency, spleen size
- Hepatic elastography (FibroScan): Non-invasive assessment of fibrosis (if not already established)
If Suspecting Malignancy
Diagnostic Tests
- Esophagogastroduodenoscopy with biopsy: Multiple biopsies from lesion and surrounding tissue; at least 6-8 biopsies for gastric lesions
- Endoscopic ultrasound (EUS): T-staging of esophageal and gastric cancers; lymph node assessment
Staging Studies
- CT chest, abdomen, and pelvis: Assess for metastatic disease
- PET-CT: For esophageal cancer staging; selected gastric cancers
- Diagnostic laparoscopy: Gastric cancer staging to exclude peritoneal disease
If Suspecting Aortoenteric Fistula
High Clinical Suspicion Required
- CT angiography: Test of choice; may show perigraft fluid, gas, pseudoaneurysm, or contrast extravasation
- Endoscopy: May visualize graft or fistula, but negative endoscopy does NOT exclude diagnosis
- Tagged red blood cell scan: Can detect intermittent or low-volume bleeding; useful when CT and endoscopy are negative
- Surgical exploration: May be necessary for definitive diagnosis and treatment
Important: Do not delay vascular surgery consultation to complete investigations if clinical suspicion is high.
When Upper Endoscopy is Non-Diagnostic
| Scenario | Next Investigation | Rationale |
|---|---|---|
| Obscured by blood; poor visualization | Repeat esophagogastroduodenoscopy after prokinetic and gastric lavage; consider angiography if brisk bleeding | Improved preparation may allow source identification; active arterial bleeding may be visible on angiography |
| No source found; melena continues | Colonoscopy to evaluate for lower GI source; video capsule endoscopy or CT enterography for small bowel | Consider mid-GI bleed from small bowel source beyond reach of standard endoscopy |
| Suspected Dieulafoy lesion (intermittent bleeding) | Repeat esophagogastroduodenoscopy during active bleeding; provocative angiography | Lesion may only be visible during active bleeding; angiography can identify and treat with embolization |
| Suspected aortoenteric fistula; endoscopy negative | CT angiography; surgical exploration | Endoscopy sensitivity is low; high clinical suspicion warrants further imaging or surgery |
| Ongoing transfusion requirement; source unclear | Angiography with possible embolization; tagged red blood cell scan (if bleeding greater than 0.1-0.5 mL/min) | Angiography is both diagnostic (active bleeding greater than 0.5 mL/min) and therapeutic (embolization) |
Role of Proton Pump Inhibitor Therapy
Evidence-Based Approach to Acid Suppression
- Pre-endoscopy proton pump inhibitor: High-dose intravenous proton pump inhibitor (e.g., pantoprazole 80 mg bolus) may downstage ulcer stigmata but does NOT replace endoscopy and does NOT reduce mortality, rebleeding, or surgery rates
- Post-endoscopy proton pump inhibitor (high-risk lesions): For Forrest Ia, Ib, IIa, IIb ulcers after endoscopic therapy—high-dose intravenous proton pump inhibitor (80 mg bolus then 8 mg/hour infusion for 72 hours) reduces rebleeding
- Low-risk lesions: Forrest IIc and III ulcers can be managed with oral proton pump inhibitor; early discharge is appropriate
Laboratory Monitoring During Hospitalization
| Test | Frequency | Purpose |
|---|---|---|
| Hemoglobin | Every 6-8 hours in active bleeding; daily when stable | Guide transfusion; detect rebleeding (drop greater than 2 g/dL) |
| Coagulation studies | Repeat after correction or if rebleeding | Ensure adequate correction; monitor for consumption coagulopathy |
| Renal function | Daily | Monitor for acute kidney injury from hypovolemia; hepatorenal syndrome in cirrhosis |
| Lactate | Every 2-6 hours during resuscitation | Monitor perfusion; lactate clearance indicates adequate resuscitation |
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways for upper gastrointestinal bleeding
Step 1: Is This Urgent? Initial Triage
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Hemodynamic instability (systolic BP less than 90 mmHg, HR greater than 120 bpm, altered mental status) | EMERGENT | Two large-bore IVs; aggressive fluid resuscitation; activate massive transfusion protocol if needed; consider ICU admission; urgent endoscopy once stabilized; if variceal suspected, start octreotide and antibiotics immediately |
| Active hematemesis or bright red blood per nasogastric tube | EMERGENT | Airway assessment (consider intubation for massive hematemesis); IV access and resuscitation; prokinetic agent; urgent endoscopy within 12 hours |
| Known or suspected liver disease with GI bleeding | EMERGENT | Assume variceal bleeding; start vasoactive drug (octreotide 50 mcg bolus then 50 mcg/hour); prophylactic antibiotics (ceftriaxone 1 g IV); endoscopy within 12 hours |
| History of aortic aneurysm repair with any GI bleeding | EMERGENT | Assume aortoenteric fistula until proven otherwise; vascular surgery consultation; CT angiography; prepare for possible emergent surgery |
| Stable vital signs, coffee-ground emesis or melena, no red flags | URGENT | IV access; laboratory studies; proton pump inhibitor; endoscopy within 24 hours; admit for observation |
| Single episode of minor hematemesis, hemodynamically stable, no comorbidities, GBS = 0 | ROUTINE | May be candidate for outpatient management; proton pump inhibitor; endoscopy within 24-48 hours as outpatient; reliable patient with close follow-up |
Step 2: Variceal or Non-Variceal Bleeding?
Suspect Variceal Bleeding If:
- Known cirrhosis or chronic liver disease
- Stigmata of chronic liver disease on examination (jaundice, ascites, spider angiomata, splenomegaly)
- History of prior variceal bleeding
- Thrombocytopenia with elevated INR
- Alcohol use disorder
- Known portal vein thrombosis
Action: Initiate variceal bleeding protocol immediately (vasoactive drug + antibiotics + urgent endoscopy)
Suspect Non-Variceal Bleeding If:
- NSAID or aspirin use
- Epigastric pain or dyspepsia
- Prior peptic ulcer disease
- Forceful vomiting before hematemesis
- No stigmata of liver disease
- Normal platelet count and coagulation
Action: Proton pump inhibitor; endoscopy within 24 hours; resuscitate as needed
Step 3: Resuscitation Algorithm
| Parameter | Target | Intervention |
|---|---|---|
| IV Access | Two large-bore (16-18 gauge) peripheral IVs; central access if peripheral access difficult | Establish immediately; consider intraosseous access in extremis |
| Fluid Resuscitation | Restore intravascular volume; target MAP greater than 65 mmHg | Crystalloid (normal saline or lactated Ringer’s); avoid over-resuscitation in variceal bleeding (may increase portal pressure) |
| Blood Transfusion | Hemoglobin target 7-8 g/dL (restrictive strategy); higher threshold (8-9 g/dL) if cardiac disease | Restrictive transfusion improves outcomes in upper GI bleeding; activate massive transfusion protocol if greater than 4 units in 1 hour needed |
| Coagulopathy Correction | INR less than 2.5 for endoscopy; platelets greater than 50,000/μL | Fresh frozen plasma, prothrombin complex concentrate, or vitamin K for warfarin reversal; platelet transfusion if thrombocytopenic and actively bleeding |
| Anticoagulant Reversal | Case-by-case decision balancing bleeding versus thrombotic risk | Warfarin: vitamin K + PCC; Dabigatran: idarucizumab; Factor Xa inhibitors: andexanet alfa or PCC; consult hematology if uncertain |
| Airway Protection | Secure airway if massive hematemesis, encephalopathy, or respiratory compromise | Elective intubation before endoscopy if high aspiration risk |
Step 4: Timing of Endoscopy
| Clinical Scenario | Recommended Timing | Rationale |
|---|---|---|
| Hemodynamically unstable despite resuscitation | Emergent (less than 6 hours) | Need for immediate source identification and hemostasis; consider angiography if too unstable for endoscopy |
| Suspected variceal bleeding | Urgent (within 12 hours) | Band ligation is definitive therapy; delay increases mortality |
| High-risk features (active hematemesis, shock index greater than 1, hemoglobin less than 8 g/dL) | Urgent (within 12 hours) | High rebleeding risk; early intervention improves outcomes |
| Stable, low-risk presentation | Within 24 hours | Standard recommendation for most upper GI bleeding; allows adequate resuscitation and preparation |
| Very low risk (GBS = 0) | Outpatient within 24-48 hours | Selected patients may avoid admission; requires reliable patient and close follow-up |
Step 5: Post-Endoscopy Management
Based on Endoscopic Findings (Peptic Ulcer Disease)
| Forrest Classification | Description | Rebleeding Risk | Management |
|---|---|---|---|
| Ia | Spurting hemorrhage | 90% | Endoscopic therapy (dual modality); high-dose IV proton pump inhibitor (80 mg bolus then 8 mg/hour × 72 hours); ICU monitoring |
| Ib | Oozing hemorrhage | 30% | Endoscopic therapy; high-dose IV proton pump inhibitor; monitored bed |
| IIa | Non-bleeding visible vessel | 50% | Endoscopic therapy; high-dose IV proton pump inhibitor; monitored bed |
| IIb | Adherent clot | 30% | Consider clot removal and treat underlying lesion; high-dose IV proton pump inhibitor or oral proton pump inhibitor |
| IIc | Flat pigmented spot | 10% | No endoscopic therapy needed; oral proton pump inhibitor; early diet; consider discharge |
| III | Clean ulcer base | 5% | No endoscopic therapy needed; oral proton pump inhibitor; early diet; early discharge |
Variceal Bleeding Post-Endoscopy
After Successful Band Ligation or Sclerotherapy:
- Continue vasoactive drug (octreotide or terlipressin) for 3-5 days
- Continue antibiotic prophylaxis for 5-7 days
- Start non-selective beta-blocker (propranolol or nadolol) before discharge for secondary prophylaxis
- Schedule repeat endoscopy in 1-2 weeks for repeat band ligation until varices eradicated
- Consider TIPS if bleeding refractory to endoscopic therapy
- Assess for liver transplant candidacy
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient rebleeds after endoscopic therapy | Resume resuscitation; assess hemodynamic status | Repeat endoscopy (second attempt at hemostasis); if fails, angiographic embolization or surgery |
| Endoscopy shows no source but melena continues | Ensure upper GI source (nasogastric lavage if not done); continue resuscitation | Repeat esophagogastroduodenoscopy with careful inspection; colonoscopy to exclude lower source; consider capsule endoscopy or CT angiography for mid-GI bleed |
| Patient on dual antiplatelet therapy (post-coronary stent) with bleeding | Do NOT stop both agents without cardiology consultation; continue aspirin if possible | Cardiology and gastroenterology joint decision; balance stent thrombosis risk versus bleeding risk; endoscopic therapy; proton pump inhibitor |
| Massive hemorrhage, patient too unstable for endoscopy | Activate massive transfusion protocol; intubate for airway protection | Interventional radiology for angiographic embolization; surgery consultation; stabilize then attempt endoscopy if possible |
| Variceal bleeding refractory to band ligation | Continue vasoactive therapy; consider balloon tamponade (Blakemore or Minnesota tube) as bridge | Urgent TIPS (transjugular intrahepatic portosystemic shunt); surgical shunt if TIPS unavailable |
| Gastric ulcer—is it malignant? | Multiple biopsies (6-8) from ulcer margins during index endoscopy | All gastric ulcers require repeat endoscopy at 6-8 weeks to document healing and repeat biopsy; malignant ulcers may initially appear benign |
| Helicobacter pylori positive on testing | Start eradication therapy before discharge | Confirm eradication with urea breath test or stool antigen 4 weeks after treatment completion (and 2 weeks off proton pump inhibitor) |
| Patient needs to resume anticoagulation | Balance thrombotic risk versus rebleeding risk; involve relevant specialists | Generally safe to resume anticoagulation 7-14 days after bleeding stops; earlier (3-7 days) if high thrombotic risk and endoscopic hemostasis achieved; proton pump inhibitor co-therapy |
Troubleshooting Refractory or Recurrent Bleeding
Ask These Questions
- Was the source correctly identified? Consider repeat endoscopy, angiography, or alternative imaging
- Was endoscopic therapy adequate? High-risk lesions require dual modality therapy; visible vessel may need multiple clips
- Is there ongoing coagulopathy? Recheck INR, platelet count; ensure adequate correction
- Is the patient still on culprit medications? Confirm NSAIDs, anticoagulants, and antiplatelet agents addressed
- Could this be a Dieulafoy lesion? May require endoscopy during active bleeding to visualize
- Could this be aortoenteric fistula? Maintain high suspicion if prior aortic surgery
- Are there multiple bleeding sources? Portal hypertensive gastropathy plus varices; ulcer plus erosive gastritis
- Is this actually a mid-GI or lower GI source? Consider capsule endoscopy, push enteroscopy, or colonoscopy
Criteria for Safe Discharge
Safe to Discharge If:
- Hemodynamically stable for at least 24 hours
- No evidence of rebleeding (stable hemoglobin, no further hematemesis or melena)
- Endoscopy shows low-risk lesion (Forrest IIc or III)
- Able to tolerate oral intake
- Adequate social support and follow-up arranged
- Medications reconciled (culprit drugs stopped or replaced)
- Patient educated on warning signs
Requires Prolonged Observation If:
- High-risk endoscopic findings (Forrest Ia, Ib, IIa, IIb)
- Ongoing transfusion requirement
- Significant comorbidities (cardiac, renal, hepatic disease)
- Uncertain diagnosis
- Social factors precluding safe discharge
- Variceal bleeding (typically 3-5 days for vasoactive therapy)
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Initial hemoglobin can be deceptively normal: In acute bleeding, hemoglobin may not drop until hemodilution occurs (6-24 hours). Never rely on a normal hemoglobin to exclude significant bleeding in an acutely symptomatic patient.
BUN:creatinine ratio greater than 30:1 suggests upper GI bleeding: Digestion of blood in the upper GI tract releases urea, elevating BUN out of proportion to creatinine. This helps distinguish upper from lower GI sources.
Restrictive transfusion strategy improves outcomes: Transfusing to a hemoglobin target of 7-8 g/dL (rather than 9-10 g/dL) reduces mortality, rebleeding, and complications in upper GI bleeding. Exception: patients with acute coronary syndrome may benefit from a higher threshold.
Prokinetics before endoscopy improve visualization: Erythromycin 250 mg IV or metoclopramide 10 mg IV given 30-90 minutes before endoscopy promotes gastric emptying, improves mucosal visualization, and reduces need for repeat endoscopy.
All gastric ulcers require biopsy and follow-up: Unlike duodenal ulcers (rarely malignant), gastric ulcers can harbor malignancy. Take multiple biopsies (6-8) and repeat endoscopy at 6-8 weeks to document healing and confirm benign nature.
Antibiotics are essential in variceal bleeding: Prophylactic antibiotics (ceftriaxone 1 g IV daily) reduce bacterial infections and mortality in cirrhotic patients with GI bleeding. Start immediately upon suspecting variceal hemorrhage—do not wait for endoscopic confirmation.
Shock index is more sensitive than BP or HR alone: Heart rate divided by systolic blood pressure greater than 1.0 identifies significant hypovolemia earlier than either vital sign alone. It predicts need for transfusion and adverse outcomes.
Helicobacter pylori eradication prevents ulcer recurrence: Without eradication, peptic ulcers recur in 60-80% of patients. With successful eradication, recurrence drops to less than 5%. Always test and treat.
Critical Pitfalls to Avoid
Forgetting aortoenteric fistula: Any GI bleeding in a patient with prior aortic surgery (even decades ago) must raise suspicion for aortoenteric fistula. A “herald bleed” may appear minor before catastrophic hemorrhage. A negative endoscopy does NOT exclude this diagnosis.
Over-transfusing in variceal bleeding: Aggressive transfusion in variceal bleeding can increase portal pressure and worsen hemorrhage. Target hemoglobin 7-8 g/dL; avoid over-resuscitation with crystalloid as well.
Missing variceal bleeding because stigmata are subtle: Not all patients with cirrhosis have obvious stigmata of chronic liver disease. Thrombocytopenia, coagulopathy, or history of alcohol use should prompt high suspicion. When in doubt, start the variceal protocol.
Delaying endoscopy in high-risk patients: Early endoscopy (within 12-24 hours) improves outcomes. Delays for “optimization” beyond what is necessary for patient safety allow rebleeding and worsen prognosis.
Using only epinephrine injection for hemostasis: Epinephrine injection alone is inferior to combination therapy. Always combine with a second modality (thermal coagulation or clips) for high-risk lesions.
Stopping all antiplatelet agents after post-stent bleeding: Abruptly stopping dual antiplatelet therapy after coronary stent placement risks stent thrombosis, which is often fatal. Continue at least aspirin if at all possible; involve cardiology in all decisions.
Assuming melena is always from the upper GI tract: While 90% of melena originates from an upper GI source, 10% comes from the small bowel or proximal colon. If upper endoscopy is negative, pursue evaluation of the lower GI tract and small bowel.
Discharging without addressing Helicobacter pylori status: Testing for Helicobacter pylori and initiating eradication therapy before discharge dramatically reduces ulcer recurrence. False-negative testing may occur during acute bleeding—consider empiric treatment or confirmatory testing after recovery.
Key Takeaways
- Upper GI bleeding remains a common medical emergency with 2-10% mortality for non-variceal and 15-20% for variceal causes—prompt recognition and treatment are essential.
- Distinguish variceal from non-variceal bleeding early—look for stigmata of chronic liver disease, thrombocytopenia, and coagulopathy. Variceal bleeding requires a specific protocol (vasoactive drugs, antibiotics, urgent band ligation).
- Use the Glasgow-Blatchford Score for pre-endoscopy risk stratification—a score of 0 identifies very low-risk patients who may be candidates for outpatient management.
- Resuscitate before endoscopy but do not delay unnecessarily—endoscopy should be performed within 24 hours for most patients, and within 12 hours for high-risk presentations.
- Adopt a restrictive transfusion strategy (hemoglobin target 7-8 g/dL)—over-transfusion worsens outcomes, especially in variceal bleeding.
- High-dose proton pump inhibitor therapy post-endoscopy is beneficial for high-risk peptic ulcers (Forrest Ia, Ib, IIa, IIb) but does not replace endoscopic therapy.
- All gastric ulcers require multiple biopsies and follow-up endoscopy to exclude malignancy—healing does not exclude cancer.
- Helicobacter pylori eradication is essential for preventing peptic ulcer recurrence—test all patients and confirm eradication after treatment.
- Never forget aortoenteric fistula in patients with prior aortic surgery—a negative endoscopy does not exclude this life-threatening diagnosis.
- Medications are a common and modifiable cause—review all NSAIDs, aspirin, anticoagulants, antiplatelet agents, and SSRIs; adjust regimens and add proton pump inhibitor prophylaxis as appropriate.
Quick Reference Algorithm
Systematic Approach to Upper Gastrointestinal Bleeding:
- Assess and stabilize: ABCs, two large-bore IVs, fluid resuscitation, vital signs monitoring, shock index calculation
- Determine severity: Hemodynamic status, volume of blood loss, need for transfusion; calculate Glasgow-Blatchford Score
- Classify as variceal or non-variceal: Look for liver disease stigmata; if variceal suspected, start vasoactive drug and antibiotics immediately
- Order baseline investigations: CBC, type and screen (or crossmatch), coagulation studies, metabolic panel, liver function tests, lactate, ECG
- Initiate proton pump inhibitor therapy: High-dose IV proton pump inhibitor (for non-variceal bleeding)
- Perform endoscopy: Timing based on risk stratification (emergent, urgent, or within 24 hours); administer prokinetic agent beforehand
- Apply endoscopic therapy: Dual modality for high-risk lesions; band ligation for esophageal varices; cyanoacrylate for gastric varices
- Post-endoscopy management: Continue acid suppression (intensity based on Forrest classification); address Helicobacter pylori; adjust medications
- Prevent recurrence: Helicobacter pylori eradication; modify or discontinue NSAIDs; proton pump inhibitor if ongoing aspirin or anticoagulation; beta-blocker and repeat band ligation for varices
- Arrange follow-up: Repeat endoscopy for gastric ulcers; confirm Helicobacter pylori eradication; outpatient surveillance for variceal patients